Name | Title | Contact Details |
---|
You can count on Rushlight Ventures to maximize the value of your intellectual property (IP). Rushlight Ventures is a leading venture studio that specializes in the monetization of defense and dual-use intellectual property created by small and mid-sized businesses conducting federally sponsored research. We are both "IP type" and "monetization path" agnostic. We can pursue value creation from your IP via licenses, asset sales, startups, joint ventures, M&A, or internal business units. We work with IP of all varieties, including products, patents, trade secrets, proprietary relationships, and know-how. At Rushlight Ventures, we provide a range of consulting and support services, including: • Licensing • Asset sales • Joint ventures • Startup and spin-out creation • Commercialization planning and TABA support Companies primarily focused on delivering high-quality research, development, testing, and evaluation services (RDT&E) and other large programs may find it challenging to be equally adept at technology commercialization. Thats why Rushlight Ventures (RLV) originated as a venture studio in 2020 within Cornerstone Research Group (CRG), its sister company and a renowned government contractor for more than 25 years. Soon after forming the venture studio, leadership realized that CRG was not the only company grappling with transition and monetization difficulties, and RLV was spun off as an independent entity in 2021. Today, RLV successfully bridges the gap between RDT&E and commercialization through its seasoned team. RLV staff possess decades of experience in new technology development and commercialization, aerospace and defense RDT&E, new company formation, financing, licensing, and mergers and acquisitions. We have the knowledge and ability to take you from now to wow.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Market USA, a full-service financial institution, was originally chartered in 1953 to serve Giant Food employees in the Mid-Atlantic region. Throughout the years our membership has grown to include additional grocery store chains such as Giant of Carlisle, Stop and Shop, and BI-LO, as well as over 80 select employer groups. As a member-owned, not-for-profit cooperative, we exist solely to bring our membership innovative products and services with low loan rates, competitive dividend rates, and low or no fees. Benefits of membership include free checking, a variety of loan and deposit products, mobile services, financial education and counseling, access to thousands of surcharge-free ATMs, discounts on insurance products, and much more. Our top priority is our members financial success. Members are our shareholders and each member has one vote. In addition, we are governed by a volunteer board of directors who look out for the best interest of members, not stockholders.
Founded in 1904, the Fédération Internationale de Football Association (FIFA) is the umbrella organisation of its members, currently 211 national football associations. Its main objectives, enshrined in its statutes, are to develop football around the world, to stage international competitions and to protect the integrity of football (against match manipulation, doping etc.). FIFA is composed of a number of political bodies (such as the FIFA Congress and the FIFA Council) and the administration. The highest political position is the FIFA President, elected every four years by FIFAs member associations. The FIFA administration, with more than 800 people from over 60 nations, is based in Zurich. It is run by the Secretary General (CEO). FIFA stages FIFA World Cups™ in various forms such as youth, mens and womens, futsal, beach soccer or club competitions. The mens FIFA World Cup™ is not only the most popular single sporting event in the world but also the financial backbone for FIFA and its efforts to develop football worldwide. The financial success of the FIFA World Cup™ allows FIFA to run a wide range of football development programmes and to provide funds, infrastructure and know-how to its member associations through the FIFA Forward Development Programme. For more information visit our website.